

Edgar Filing: PFIZER INC - Form 8-K

PFIZER INC  
Form 8-K  
June 17, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report:  
June 17, 2003

Date of earliest event reported:  
June 17, 2003

PFIZER INC.

-----  
(Exact name of registrant as specified in its charter)

Delaware

001-03619

13-5315170

-----  
(State or other jurisdiction  
of incorporation)

(Commission File  
Number)

(I.R.S. Employer  
Identification No.)

235 East 42nd Street, New York, New York

10017

-----  
(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code  
(212) 573-2323

-----  
(Former name or former address, if changed since last report.)

Item 12. Results of Operations and Financial Condition

On June 17, 2003, Pfizer Inc. ("Pfizer") will hold a meeting with securities analysts in New York, New York. Pfizer will present certain financial information reflecting its merger with Pharmacia Corporation, completed on April 16, 2003. Pfizer will report, among other things, that in relation to pro-forma 2002 Pfizer/Pharmacia combined revenue of \$45 billion, 2004 revenue of \$54 billion represents approximately 10% compound annual revenue growth. Adjusted diluted earnings per share of \$2.13 in 2004 represents 16% compound growth from 2002. A copy of a visual aid including this information is attached to this Report as Exhibits 99 and is incorporated by reference.

## Edgar Filing: PFIZER INC - Form 8-K

A reconciliation of Pfizer's revenues for the year ended December 31, 2002 as reported in its 2002 Annual Report to Shareholders to pro-forma 2002 Pfizer/Pharmacia combined revenue for the year ended December 31, 2002 is as follows:

(\$ in Millions)	Year Ended December 31, 2002
Pfizer reported revenues	\$32,373
Pharmacia reported revenues	13,993
Proforma adjustment (*)	(1,368)
	-----
Pfizer/Pharmacia combined revenue	\$44,998

\* To eliminate transactions between Pfizer and Pharmacia which occurred under the Celebrex and Bextra marketing agreements.

Pfizer will file pro-forma financial statements relating to the acquisition of Pharmacia, as required pursuant to Item 7(b) of Report on Form 8-K, on or before June 30, 2003. The announcement of the acquisition of Pharmacia was reported on Form 8-K filed on April 16, 2003.

Item 7(c). Financial Statements Exhibits

Exhibit	Description
-----	-----
99	Visual aid used at securities analyst presentation by Pfizer Inc.

2

Signature

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

-----  
(Registrant)

Date: June 17, 2003

/s/ Margaret M. Foran

-----  
Name: Margaret M. Foran  
Title: Vice President - Corporate  
Governance and Secretary

EXHIBIT INDEX

Edgar Filing: PFIZER INC - Form 8-K

Exhibit

-----

Description

-----

99

Visual aid used at securities analyst presentation by Pfizer Inc.